The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog is intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at www.Vicus.com, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Support this site

    If you found the information here helpful, please consider supporting this site.If you found the information here helpful, please consider supporting this site.

  • Recent Posts

  • Recent Comments

    Response to cannabis by non-smokers with MS

    Researchers from Italy and the US studied changes in psychological symptoms, reasoning, abuse, tolerability, quality of life, fatigue, and ability to control movement in patients with multiple sclerosis (MS) who had never before been exposed to cannabis.

    First, the details.

    • 17 patients with MS who had not been exposed to cannabis were studied over 8-weeks.
    • They were randomly divided into cannabis (cannabis plant extract; Sativex) and placebo groups. Then reversed so everybody took both treatments — crossover design.
    • Patients and researchers didn’t know the treatment given — double-blinded.
    • Each treatment lasted 3 weeks.
    • A battery of evaluative tools was used to assess the findings.

    And, the results.

    • There were no significant differences in any parameter studied.
    • There was a significant positive correlation between Delta-9-tetrahydrocannabinol blood levels and scores in “interpersonal sensitivity,” “aggressive behavior,” and “paranoiac tendencies.”
    • No serious side effects, abuse tendencies, or direct withdrawal symptoms were reported.

    The bottom line?
    The authors concluded, “Cannabinoid treatment did not induce psychopathology and did not impair cognition [reasoning] in cannabis-naive patients with MS.”

    However, higher blood levels of Delta-9-tetrahydrocannabinol (higher than used in treatment) were associated with greater interpersonal sensitivity, aggressiveness, and paranoiac features.

    11/8/08 11:07 JR

    Leave a Comment

    XHTML: Line-breaks are automatic. Available tags are <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>